Introduction {#sec1}
============

Urachal adenocarcinoma is rare constituting 0.17 to 0.34% of all bladder cancers and 20 to 39% of primary bladder adenocarcinomas.[@bib1] We report an urachal adenocarcinoma managed surgically emphasizing importance of enbloc umbilectomy with urachal remnant excision and negative surgical margins as important prognostic markers.

Case report {#sec1.1}
-----------

A 35-year-old female presented with swelling over lower anterior abdominal wall since 3 months with associated ulceration and serous discharge since 10 days with occasional hematuria. Local examination revealed 10 × 8 cm swelling in hypogastrium with restricted mobility, firm to cystic consistency and overlying 5 × 4 cm ulcer ([Fig. 1](#fig1){ref-type="fig"}). Wedge biopsy has shown grade 1, adenocarcinoma. Levels of Ca-125, CEA and CA19.9 were normal. Urine analysis suggestive of microscopic hematuria with no growth in culture-sensitivity. Imaging ([Fig. 1](#fig1){ref-type="fig"}) was suggestive of heterogeneously enhancing lesion of 70 × 104\*59 mm involving antero-superior end of urinary bladder, superiorly extending up to umbilicus; involving overlying abdominal wall and skin with few areas of ulceration; bilateral enlarged external iliac nodes largest 10 × 12 mm on right side. Cystoscopy shown erythematous mucosa at dome of bladder. Colonoscopy was normal.Fig. 1a. Ulcerated swelling over the hypogastric area. b. MR sagittal T2 image showing tumour mass (arrow) at dome of bladder with infiltration of anterior abdominal wall and sigmoid colon (arrow head) posteriorly. c. CT axial image showing tumour mass with necrotic areas. d. Circular periumbilical incision (arrow) and elliptical incision (arrow head) around tumour mass. e. Umbilicus along with attached urachus in continuity with the mass and bladder. f. Tumour (T) infiltrating sigmoid colon (arrow head). g. Resected sigmoid colon attached to tumour with clamped ends of colon. h. Bladder incision marked for cystectomy.Fig. 1

After informed and written consent, intraoperatively two separate incisions; one circular incision around umbilicus and another elliptically around abdominal wall mass was planned. Flaps elevated and incision deepened. Umbilicus excised in contiguous with urachal remnant till the level of tumour mass. Tumour mass located at dome of bladder, infiltrating anterior abdominal wall and 4cm length of sigmoid colon. Explored solid organs and peritoneal cavity normal. Partial cystectomy along with en-mass excision of tumour mass + resection of involved sigmoid colon with bilateral pelvic lymphadenectomy; bladder and sigmoid colon repair was performed ([Fig. 2](#fig2){ref-type="fig"}). Prolene mesh used for abdominal wall reconstruction. Operative duration was 180 min with 300ml blood loss. One unit packed cell transfusion given post-operatively. Patient kept nil per oral for 5 days and IV antibiotics for 7 days. Drains removed on post op day 6. Patient discharged on post op day 8 and catheter removed on day 14.Fig. 2a. Opened up bladder with adequate negative margin. b. Sutured bladder wall. c. Resected specimen -- anterior view. d. Resected specimen -- posterior view. e. Resected specimen -- lateral view. f. Resected specimen showing umbilicus (arrow) in contiguous with urachus (arrow heads) and tumour mass infiltrating rectus muscle, sheath, subcutaneous tissue and skin anteriorly and sigmoid colon posteriorly. g. Healed scar at follow up.Fig. 2

Patient was doing well in follow up period with well healed scar ([Fig. 2](#fig2){ref-type="fig"}). Histopathology ([Fig. 3](#fig3){ref-type="fig"}) suggestive of urachal adenocarcinoma, grade II with areas of necrosis extending into skin of anterior abdominal wall; infiltrates into serosa, muscular layer of urinary bladder and extends up to mucosa projecting into bladder cavity; infiltrates into serosa and muscular layer of sigmoid colon with normal overlying mucosa; Resected margins of skin, sigmoid colon, bladder wall and inked soft tissue margins are free of tumour. All eleven (right) and thirteen (left) pelvic nodes were negative.Fig. 3a. Low power H&E view showing normal surface urothelium (arrow) and muscularis of bladder (\#) with tumour (\*) encroaching form outside in -- characteristic of urachal tumors. b. CDX2 nuclear positive. c. β-Catenin Nuclear negative.Fig. 3

No adjuvant therapy was considered as surgical margins and nodes were negative. At 12 months follow up, patient was asymptomatic and with normal imaging.

Discussion {#sec2}
==========

Mucin secreting or non-secreting adenocarcinomas arise from innermost epithelial layer of urachus, with lesser variants being sarcomas, transitional cell and squamous cell carcinomas. Pelvic lymph nodes are regional nodes.

Most common symptoms are abdominal pain, hematuria, palpable suprapubic mass, irritative voiding, discharge from umbilicus. Nonspecific nature of most symptoms delays diagnosis leading to locally advanced presentation. Differential diagnosis includes primary bladder adenocarcinoma arising in 15% of cases in dome of bladder, invasion from adenocarcinomas of rectum, endometrium, ovary, prostate, deposits from upper abdominal solid organ malignancy.

Diagnostic pathologic criteria for urachal tumors include: Lesion centered in anterior wall or dome of bladder; predominant invasion of muscularis or deeper tissues with sharp demarcation between tumor and surface bladder urothelium; surface urothelium is free of glandular or polypoid proliferation; no carcinoma in situ or glandular metaplasia other than cystitis glandularis; presence of urachal remnants is helpful but identifiable only in 32% of cases; no primary adenocarcinoma elsewhere.[@bib2] Bladder dome adenocarcinomas should be considered as urachal adenocarcinomas, because approach and management decisions are similar. Immunohistochemistry plays important role in differentiating as primary urachal adenocarcinoma is positive for CK7 with variable CK20 and CDX2 positivity but beta-catenin is negative which is inverse in colonic adenocarcinomas.

Sheldon et al. based on observations from 117 cases first proposed surgico-pathological staging in 1983. Stage I-no invasion beyond the urachal mucosa, Stage II-invasion confined to the urachus, Stage III-local extension into bladder (IIIA), abdominal wall (IIIB), peritoneum (IIIC) or viscera other than the bladder (IIID) and Stage IV-metastases to the regional lymph nodes (IVA) or distant sites (IVB). 83% of patients in their analysis presented in stage III disease with predominant IIIA.[@bib1]

Henly et al. proposed modifications referred to as Mayo staging system as follows:Stage I-tumors confined to urachus and/or bladder; Stage II-tumors extending beyond muscular layer of urachus and/or bladder; Stage III-tumors infiltrating regional lymph nodes; Stage IV-tumors infiltrating non-regional lymph nodes or other distant sites. Both Mayo and Sheldon staging systems are highly correlated (p = .82; PSP\<0.001) and compared favorably in their ability to predict survival. Sheldon staging with 8 stage categories was found to be over specified and unnecessarily complex, due to low number of patients in four of its staging strata (Stage I, IIIB, IIIC, IIID) than the simpler four category Mayo staging as proved by Akaike Information Criterion (AIC).[@bib3]

Local control in form of surgical approach remains main stay first line treatment and more effective than radiotherapy for resectable lesion. Surgery includes partial cystectomy, tumor debulking with enbloc umbilectomy and urachectomy with negative surgical margins.7% of urachal cancers have umbilicus involvement and 81% of patients surviving at 5 years have urachal ligament excised. Umbilectomy and enbloc urachal remnant excision is justified to improve recurrence and survival rates. Survival benefit of radical cystectomy over partial cystectomy is not proven in existing literature and also difficult to assess due to rarity.[@bib1]^,^[@bib3]^,^[@bib4]

Grade of tumour, negative surgical margins, positive nodes, failure to perform umbilectomy are independent predictors of survival.[@bib3]^,^[@bib4] Local recurrence most often occurs in first two years with sites being pelvis followed by bladder and abdominal wound. Distant metastases usually occurs late with lung being most common site.[@bib1]

Adjuvant therapy is indicated for patients who have positive surgical margins or positive lymph nodes. No standard protocol for adjuvant chemotherapy. Most commonly used agents were cisplatin, paclitaxel, doxorubicin and FOLFOX. Use of adjuvant therapy was not associated with significant improvement in cancer-specific survival (HR,1.6; 95%CI, 0.7--3.6) and response rates up to 48% documented in unresectable or metastatic disease. Overall 5-year cancer specific survival ranges from 40% to 51% in published series, which is significantly better than those with non urachal adenocarcinomas and urothelial carcinomas of bladder.[@bib3], [@bib4], [@bib5]

Conclusion {#sec3}
==========

Urachal adenocarcinomas are rare, presents in advanced stages, but better prognosis than other bladder tumors. Clinical diagnosis supported with imaging, initial radical surgical management to achieve negative margins with umbilectomy and urachal remnant excision, timely surveillance can help to improve outcomes and survival.
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